Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Drops By 27.9%

Adlai Nortye Ltd. (NASDAQ:ANL) saw a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 3,100 shares, a drop of 27.9% from the October 15th total of 4,300 shares. Based on an average daily trading volume, of 14,400 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Adlai Nortye in a research note on Monday.

Adlai Nortye Trading Up 2.1 %

Shares of NASDAQ:ANL traded up $0.07 during mid-day trading on Friday, reaching $3.34. 18,978 shares of the company traded hands, compared to its average volume of 11,677. Adlai Nortye has a 52 week low of $1.85 and a 52 week high of $17.48. The company’s 50 day moving average price is $2.18 and its 200-day moving average price is $4.51.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.